Zobrazeno 1 - 10
of 272
pro vyhledávání: '"Giuseppe Lo Russo"'
Autor:
Sun Min Lim, Solange Peters, Ana Laura Ortega Granados, Gustavo dix Junqueira Pinto, Christian Sebastián Fuentes, Giuseppe Lo Russo, Michael Schenker, Jin Seok Ahn, Martin Reck, Zsolt Szijgyarto, Neda Huseinovic, Eleftherios Zografos, Elena Buss, Neda Stjepanovic, Sean O’Donnell, Filippo de Marinis
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
Abstract PERLA is a global, double-blind, parallel phase II trial (NCT04581824) comparing efficacy and safety of anti–PD-1 antibodies dostarlimab and pembrolizumab, plus chemotherapy (DCT and PCT, respectively) as first-line treatment in patients w
Externí odkaz:
https://doaj.org/article/6e906fdccdde435787415eaa66c8249f
Autor:
Rosalba Miceli, Hanna Eriksson, Giuseppe Lo Russo, Salvatore Alfieri, Maria Moksnes Bjaanæs, Filippo Pietrantonio, Loris De Cecco, Arsela Prelaj, Claudia Proto, Johan Franzén, Deirdre McDonnell, José Javier Berenguer Pina, Teresa Beninato, Laura Mazzeo, Patrizia Giannatempo, Elena Verzoni, John Crown, Åslaug Helland, Alexander Eustace
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background: Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in various cancers. ICI treatment is associated with the incidence of immune-related adverse events (irAEs) which can affect any organ. Data on irAEs occurrence in r
Externí odkaz:
https://doaj.org/article/104cb507efb6499da6d34e4000166944
Autor:
Filippo de Braud, Valter Torri, Giuseppe Lo Russo, Claudia Proto, Roberto Ferrara, Monica Ganzinelli, Marina Chiara Garassino, Giuseppe Viscardi, Giorgio Trinchieri, Mario Occhipinti, Rita Leporati, Marta Brambilla, Luca Agnelli, Silvia Brich, Francesco Sgambelluri, Roberta Mortarini, Andrea Anichini, Leonardo Provenzano, Daniele Lorenzini, Arsela Prelaj, James Dolezal, Teresa Beninato, Tiziana Triulzi, Alessandra Fabbri, Laura Mazzeo, Andrea Spagnoletti, Vanja Miskovic, Alessandra Laura Giulia Pedrocchi, Francesco Trovo', Sara Manglaviti, Claudia Giani, Paolo Ambrosini, Andrea Franza, John McCulloch, Tommaso Torelli, Giancarlo Pruneri
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023)
Background Chemoimmunotherapy represents the standard of care for patients with advanced non-small cell lung cancer (NSCLC) and programmed death-ligand 1 (PD-L1)
Externí odkaz:
https://doaj.org/article/0391ecab2ee246659837c5b760a7cc74
Autor:
Giannis Mountzios, MD, PhD, David Planchard, MD, PhD, Giulio Metro, MD, PhD, Dora Tsiouda, Arsela Prelaj, MD, Sofia Lampaki, MD, PhD, Walid Shalata, MD, Mariona Riudavets, Petros Christopoulos, MD, PhD, Nicolas Girard, MD, PhD, Víctor Albarrán-Artahona, Rosario Garcia Campelo, MD, PhD, Konstantinos Samitas, MD, PhD, Giuseppe Luigi Banna, MD, Ioannis Boukovinas, MD, PhD, Abed Agbarya, MD, PhD, Anna Koumarianou, MD, Eleni-Isidora Perdikouri, Paris Kosmidis, Helena Linardou, MD, PhD, David Mauri, MD, PhD, Dimitrios Mavroudis, MD, PhD, Ilias Athanasiadis, MD, PhD, Haralambos Kalofonos, Nikolaos Xenidis, MD, PhD, Ippokratis Korantzis, MD, Alexandros Ardavanis, Grigorios Rallis, MD, Achille Bottiglieri, Konstantinos Efthymiadis, MD, Georgios Oikonomopoulos, MD, Alexandros Kokkalis, MD, Emmanouil Saloustros, MD, PhD, Nikolaos Tsoukalas, MD, Dimitra Bartzi, MD, Panagiota Economopoulou, Amanda Psyrri, MD, PhD, Martin Reck, Giuseppe Lo Russo, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 1, Pp 100433- (2023)
Introduction: Real-world evidence regarding molecular epidemiology and management patterns of patients with EGFR exon-20 mutated, advanced NSCLC outside the context of clinical trials is lacking. Methods: We created a European registry for patients w
Externí odkaz:
https://doaj.org/article/1da16fe8f3c8428eb04732eb21d2f835
Autor:
Arsela Prelaj, Edoardo Gregorio Galli, Vanja Miskovic, Mattia Pesenti, Giuseppe Viscardi, Benedetta Pedica, Laura Mazzeo, Achille Bottiglieri, Leonardo Provenzano, Andrea Spagnoletti, Roberto Marinacci, Alessandro De Toma, Claudia Proto, Roberto Ferrara, Marta Brambilla, Mario Occhipinti, Sara Manglaviti, Giulia Galli, Diego Signorelli, Claudia Giani, Teresa Beninato, Chiara Carlotta Pircher, Alessandro Rametta, Sokol Kosta, Michele Zanitti, Maria Rosa Di Mauro, Arturo Rinaldi, Settimio Di Gregorio, Martinetti Antonia, Marina Chiara Garassino, Filippo G. M. de Braud, Marcello Restelli, Giuseppe Lo Russo, Monica Ganzinelli, Francesco Trovò, Alessandra Laura Giulia Pedrocchi
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
IntroductionArtificial Intelligence (AI) methods are being increasingly investigated as a means to generate predictive models applicable in the clinical practice. In this study, we developed a model to predict the efficacy of immunotherapy (IO) in pa
Externí odkaz:
https://doaj.org/article/c99b6a5fcaed44e39c58687c3976c7f5
Autor:
Diego Signorelli, Patrizia Ghidotti, Claudia Proto, Marta Brambilla, Alessandro De Toma, Roberto Ferrara, Giulia Galli, Monica Ganzinelli, Giuseppe Lo Russo, Arsela Prelaj, Mario Occhipinti, Giuseppe Viscardi, Valentina Capizzuto, Francesca Pontis, Ilaria Petraroia, Anna Maria Ferretti, Mario Paolo Colombo, Valter Torri, Gabriella Sozzi, Marina Chiara Garassino, Elena Jachetti, Orazio Fortunato
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
PD-L1 in tumor cells is the only used biomarker for anti PD1/PD-L1 immune-checkpoints inhibitors (ICI) in Non Small Cell Lung Cancer (NSCLC) patients. However, this parameter is inaccurate to predict response, especially in patients with low tumor PD
Externí odkaz:
https://doaj.org/article/ab5e8307dc3647979bd096212900848c
Autor:
Arsela Prelaj, Achille Bottiglieri, Gajanan Bhat, Rocky Washington, Giuseppina Calareso, Gabriella Francesca Greco, Roberto Ferrara, Marta Brambilla, Alessandro De Toma, Mario Occhipinti, Sara Manglaviti, Alberto Soro, Monica Ganzinelli, Giuseppe Lo Russo, Claudia Proto
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Among the several next-generation tyrosine kinase inhibitors (TKIs) tested against uncommon EFGR alterations, poziotinib has been demonstrated to be a powerful agent for metastatic non-small-cell lung cancer (mNSCLC) with aberrations in HER2 exon 20,
Externí odkaz:
https://doaj.org/article/737d107e33f34e698cd951a3dca78457
Autor:
Marta Brambilla, Giuseppe Lo Russo, Roberto Ferrara, Sara Manglaviti, Marina Chiara Garassino, Mario Occhipinti
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 1, Iss 6, Pp 427-433 (2020)
Hyperprogressive disease (HPD) is a novel pattern of response during immunotherapy treatment. Several retrospective studies have evaluated its prevalence among various cancer types and, in particular, in non-small cell lung cancer patients, based on
Externí odkaz:
https://doaj.org/article/98d68b26669d4816b5dbb0f1ebae41f6
Autor:
Annalisa Trama, Claudia Proto, Diego Signorelli, Marina C. Garassino, Giuseppe Lo Russo, Monica Ganzinelli, Arsela Prelaj, Carolina Mensi, Manuela Gangemi, Valerio Gennaro, Elisabetta Chellini, Adele Caldarella, Italo F. Angelillo, Valeria Ascoli, Cristiana Pascucci, Giovanna Tagliabue, Rosanna Cusimano, Francesca Bella, Fabio Falcini, Enzo Merler, Giuseppe Masanotti, Antonio Ziino, Maria Michiara, Gemma Gola, Cinzia Storchi, Lucia Mangone, Maria F. Vitale, Claudia Cirilli, Rosario Tumino, Tiziana Scuderi, Anna C. Fanetti, Silvano Piffer, Marcello Tiseo, Gemma Gatta, Laura Botta, the LUME study WG
Publikováno v:
Thoracic Cancer, Vol 11, Iss 6, Pp 1661-1669 (2020)
Abstract Background Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. Centralization of rare cancer in dedicated centers is recommended to ensure expertise, multidisciplinarity and access to innovation. In Italy, expert cen
Externí odkaz:
https://doaj.org/article/02f86e80f4c448e49c3063f248286927
Autor:
Gian Paolo Spinelli, Evelina Miele, Alessandra Anna Prete, Giuseppe Lo Russo, Alessandro Di Marzo, Claudio Di Cristofano, Silverio Tomao
Publikováno v:
Journal of Medical Case Reports, Vol 13, Iss 1, Pp 1-5 (2019)
Abstract Background Adenoid cystic carcinoma of the trachea is a rare tumor, characterized by slow growth and low rate of local and distant metastasis. When achievable, complete surgical resection represents the optimal treatment approach, with the h
Externí odkaz:
https://doaj.org/article/5a04f256048c48aa86e4351b538521a9